secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000917520-25-000060
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026
--------------------------------------------------------------------------------

- Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
- Ratio steps down to 4.75:1 (Sep 2026), 4.50:1 (Dec 2026), and 4.00:1 (Mar 2027 onward).
- No increase in total indebtedness; temporary restrictions on investments, liens, and restricted payments during Covenant Relief Period.
- Amendment effective June 6, 2025, to Seventh Amended and Restated Credit Agreement dated March 24, 2023.
- Company temporarily prohibited from using leverage 'step-up' for permitted acquisitions during Covenant Relief Period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000060/0000917520-25-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000060/iart-20250606.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer